



BioHealth: NEWSLETTER N°1

The Cluster of Health Sciences & Technologies - Luxembourg



TABLE OF CONTENTS

Introducing the BioHealth Cluster

News | 2 - 8

- > The BioHealth Cluster; reinforcing trans-national collaborations at the 5th Healthcare brokerage event - Nancy
- > Successful meetings on the theme "Potential for the development of the agro-food sector supported by public research in Luxembourg"
- > Signing of a collaborative agreement between Luxinnovation and CRP-Santé: a privileged partnership
- > Launch of the Research Laboratory for Sports Medicine - CRP-Santé
- > Prof Rudi BALLING recruited as Director of new Centre for Systems Biology
- > ABL S.A. TherapyEdge & RightToCare successfully launch the new TherapyEdge™ Down Referral Software Patient Management System
- > New Research Laboratory at the CRP-Gabriel Lippmann
- > Chinese Medicinal Plant Research at the Plant Molecular Biology Laboratory
- > A road map for the development of the European Agro-food industry

Zoom on... | 9

Simeda Medical S.A.

Call for proposals | 10 - 11

- > National Research Fund (FNR)
- > The 7th Framework Programme (FP7)

Agenda | 10 - 12

Contacts | 12



Left to right : Ms Céline TARRAUBE, Project Manager, Luxinnovation, Mr Marco WALENTINY, President of Luxinnovation, Mr Jeannot KRECKE, Minister of the Economy and Foreign Trade

Introducing the BioHealth Cluster

BioHealth, the Cluster of Health Sciences and Technologies in Luxembourg, was launched at the end of September 2008 by Luxinnovation, the National Agency for Innovation and Research, with the participation of Mr Jeannot Krecké, Minister of the Economy and Foreign Trade.

The Cluster covers different fields of health technologies such as Medical Devices, Bioinformatics, Biomaterials, Imaging and Technology Platforms. Research efforts in Luxembourg are currently concentrated on several axes such as Immunology, Cardiovascular and Neurodegenerative Diseases, Oncology, etc., which will all be supported by the Cluster.

The BioHealth Cluster aims to promote cooperation between companies and public research organisations, and thereby stimulating research, technological development and innovation both in Luxembourg and on an international level. The Cluster provides personalised services and numerous benefits and positions itself as an exchange and networking platform.

It allows actors to strengthen their R&D and innovation capacities by participating in thematic working groups on scientific or technological topics. Participating companies and public research laboratories can explore opportunities for national and international collaboration, thereby creating partnerships between the private and public sectors. The Cluster also provides information and communication services such as an information and technology watch or participation of various events (conferences, training events, institutional research visits in Luxembourg or within the Greater Region, etc.).

The Cluster has edited a Directory of Scientific and Technological Skills that introduces the capabilities of private companies and public research institutes in Luxembourg.

> The Directory is free of charge and available on demand or downloadable via the link:

<http://www.luxinnovation.lu/site/content/FR/1154/1156/1162/1324/C6200/>



30/09/2008
Launch Conference of the BioHealth Cluster



The BioHealth Newsletter is edited by: Luxinnovation, the National Agency for Innovation and Research

The BioHealth Cluster; reinforcing trans-national collaborations at the 5th Healthcare brokerage event - Nancy

On the 18th June 2009, the Centre Lorrain des Technologies de la Santé (CLTS) organised its 5th Healthcare brokerage event in Nancy (Fr), enabling companies from the Greater Region to meet and discuss potential new partnerships. For the last few years this event has given companies, care facilities and research centres the opportunity to strengthen their collaborations with each other.

The Luxembourgish Cluster of Health Sciences & Technologies, BioHealth, coordinated by Luxinnovation, was represented at this year's event. The Cluster aims, among other things, to promote and strengthen synergies and collaborations between the private and public sectors and to develop trans-national collaborations. Two Luxembourgish companies, members of the BioHealth Cluster, were present on Luxinnovation's stand to introduce their products and services.

Actimage S.A., which is active in the information and communication sector, presented a project that was performed in collaboration with the Centre Européen d'Etude du Diabète (CEED) and the University of Technology Belford-Montbéliard on the subject of Type 1 diabetes, which was designed to show how, through an intelligent aid software developed for pocket PC's and mobile phones, the daily management of their disease could be facilitated.

New2DM S.A., which designs and fabricates implantable medical devices (hip replacements, spinal and dental implants and bone substitutes) in partnership with international surgical groups, also presented their range of products at the Healthcare brokerage event. New2DM's implantable medical devices are used in over 20 European

countries, including: France, Belgium, Luxembourg, Germany, Italy, Spain, etc.

The key theme of this year's event was "Sustainable Development in Hospitals", subject on which numerous exchanges and accounts of experiences gained within the Greater Region were given.

Luxembourg was represented by the Centre Hospitalier Emile Mayrisch (Esch-sur-Alzette) whose Technical Director, Mr Henri HINTERSCHEID, gave a presentation on sustainable development at the Centre Hospitalier.

Mr HINTERSCHEID went on to explain how the Centre Hospitalier is the most advanced hospital in this domain in Luxembourg and how it is expanding its site in Esch-sur-Alzette by constructing energy efficient buildings.

A large part of the event's success came with the B2B meetings as they enabled companies to communicate with each other directly, giving the opportunity to exchange ideas, develop contacts and even establish new partnerships. This opportunity for companies to interact directly with each other in one place was a vital step in potentially establishing a better understanding and giving a clearer idea of the specialisations of the participating companies and how they could help each other by working together. The event showed the importance and the great advantages of being part of a Cluster.

The 5th Healthcare brokerage event in Nancy proved to be a big success for Actimage S.A. and New2DM S.A. as well as the BioHealth Cluster and Luxinnovation.

Successful meetings on the theme "Potential for the development of the agro-food sector supported by public research in Luxembourg"

The meat and cereal sectors were put in the spotlight during two workshops organised by the Nutrition and Toxicology Research Unit (NuTox) of the Environment and Agro-biotechnologies Department (EVA) of the Public Research Centre Gabriel Lippmann, held on the 6th and 13th July 2009.



Organised in collaboration with Luxinnovation, the National Agency for Innovation and Research, the Chamber of Commerce, the Chamber of Skilled Crafts and Fedil - Business Federation Luxembourg, the objectives for the workshops were to:

- understand the needs of these two key sectors in Luxembourg;
- find common themes of interest;
- .../...



© Luxinnovation

.../...

- identify potential synergies in order to create collaborations between the private and public sectors;
- strengthen the competitiveness of the Luxembourgish agro-food sector.

By way of introduction and in order to define the possible nature of collaborations between the private and public sectors, Ms Céline TARRAUBE, Project Manager at Luxinnovation, presented these meetings as being an integral part of the activities of the BioHealth Cluster.

Coordinated by Luxinnovation, the Cluster of Health Sciences and Technologies defines its role as an exchange and networking platform between private and public actors.

Dr Lucien HOFFMANN, Scientific Director of EVA, presented the Department's objectives by emphasising EVA's interest in R&D cooperations in response to the needs of the actors in the Luxembourgish agro-food sector.

Dr Torsten BOHN, Head of the NuTox Laboratory, then explained the laboratory's activities as well as the different research projects currently being undertaken. He later went on to list the various possibilities for collaboration with the agro-food sector, such as food quality and security or health and nutrition.

At the end of the workshop, participants were given the opportunity to visit EVA's facilities such as the platform for analytical chemistry and the microbiology laboratories. In addition, participants were given the opportunity to discover the recently inaugurated eco-technologies demonstration laboratory, which provides a unique opportunity to measure and record the levels of biogas emitted by organic waste from the agro-food sector as a source of energy.

These visits enabled the participants to discover the equipment available to EVA in order to do their research projects, which then lead to a Q&A session with the laboratory staff. The orientation of the discussions dedicated to the meat sector was based on the speech by Mr Jean-Marie OSWALD, President of the Fédération Nationale des Patrons Bouchers-Charcutiers du Grand-Duché de Luxembourg. In his introductory speech, he underlined the lack of a reference database on the subject of salt, among other things.

Other themes such as the nutritional value and nutritional composition of meats, offals and cooked meats and the valorisation of meat waste were all of importance to the participants and responded to their concerns.

The discussions with the actors of the cereal sector were on themes linked to the increasing use of pesticides and fertiliser on cereals and to the importance of developing sampling and analysis methods for mycotoxines, as mentioned in the presentation by Mr Edmond MULLER, President of the Fédération des Industries Agro-Alimentaires Luxembourgeoises. He also underlined the need for the sector to invest in innovation in order to stay competitive, a concern shared by Mr Henri WAGENER, President of the Fédération des Patrons Boulangers-Pâtisseries du Grand-Duché de Luxembourg.

These round tables about the issues and views of the agro-food sector in Luxembourg concluded the discussion sessions.

The two workshops were conducive to open discussions between EVA and the actors of the cereal and meat sectors, thus helping to reinforce the competitiveness of the agro-food sector in Luxembourg whilst favouring future potential collaborations between the public and private sectors.

> www.lippmann.lu



© Luxinnovation



© Luxinnovation

Left to right : Mr Marco Valentiny, President of Luxinnovation, Mr Frank GANSEN, President of the CRP-Santé, Dr Jean-Claude SCHMIT, General Manager of the CRP-Santé.

Signing of a collaborative agreement between Luxinnovation and CRP-Santé: a privileged partnership

On the 3rd July 2009, the Board of the Public Research Centre for Health (CRP-Santé) and Luxinnovation signed a collaborative agreement aimed at strengthening the collaboration between the two organisations. This privileged partnership constitutes a new step towards structuring the National Innovation System in Luxembourg.

The BioHealth Cluster will play a key role in the topics covered by the convention, notably in the efforts of the CRP-Santé to collaborate with the private sector and by increasing the visibility of the skills of the CRP-Santé.

Launch of the Research Laboratory for Sports Medicine - CRP-Santé: Three main keys in the starting blocks

On Tuesday, March 7th 2009, the Public Research Centre for Health (CRP-Santé) inaugurated the Research Laboratory for Sports Medicine, newly created within the institution, in partnership with the Centre Hospitalier de Luxembourg (CHL). Although CRP-Santé has only just developed this new laboratory, the Sports and Health thematic has been around within CRP-Santé since 2007. If this initiative was able to materialise, it was due to the determination of several actors, the Ministerial Department of Sports, the pioneering work of the Centre for Musculoskeletal Medicine in Sports and Prevention of the Centre Hospitalier de Luxembourg - Clinique d'Eich who paved the way. Return to a strong start in collaborations.

It's official, the Public Research Centre for Health now has a new research unit among its 15 units, bringing together the 240 institutional collaborators.

The foundations of the newly created Research Laboratory for Sports Medicine lie in the agreement signed between the Ministerial Department of Sports and CRP-Santé as well as in the agreement signed with CHL at the end of the inauguration of the laboratory. According to the definition of the World Health Organisation, "sports medicine analyses the influence of movement, training and sports, as well as the inactivity of healthy and sick people of any age, in order to provide useful information on prevention, therapy, rehabilitation and sports".

New domain, new competences: The Public Research Centre for Health has once again chosen to focus on a component that touches on major societal issues, in collaboration with key Luxembourgish partners: The Ministerial Department of Sports, The Luxembourgish Olympics and Sports Committee (COSL), The Ministry of Culture, Higher Education and Research and the National Scientific Societies for Sports Medicine and Sports Physiotherapy are closely involved in this initiative.



© Luxinnovation

Left to right : Dr Jean-Claude SCHMIT, General Manager of the CRP-Santé, Mr Frank GANSEN, President of the CRP-Santé, Dr André KERSCHEN, Director of the Centre Hospitalier de Luxembourg, Dr François SCHNEIDER, Vice President of the CRP-Santé.

After the success of several initial projects within this domain since 2007, the Research Laboratory for Sports Medicine is focusing its new research domains on three key themes within the Grand Duchy:

- **The prevention, treatment and reduction of sports injuries:** the first cause of injuries amongst younger people. The Research Laboratory for Sports Medicine's objective: monitor the injuries, most notably within the "Sportlycée" (Lycée Aline Mayrisch) and among other research projects such as injury prevention within the semi-marathon training, which is carried out by several sports groups at the Sports and Cultural Centre Coque.
- **"Well ageing":** In the context of an ageing population, an "active" lifestyle enables people to keep their autonomy, the objective being to improve the life quality of every individual. The laboratory's objective: develop therapeutic strategies allowing aged people to keep or re-gain their active lifestyles and more precisely concerning musculoskeletal pathologies.
- **The influence of physical activity on chronic diseases:** enabling primary prevention (the disease won't be able to settle), secondary prevention (the disease is present but isn't evolving) and tertiary prevention (comorbidity).

The results of these researches will help companies with their strategic decisions in the Sports and Health domain and will undoubtedly direct and advise the policies in these areas within the Grand Duchy. The Research Laboratory for Sports Medicine will also allow CRP-Santé to reinforce its position internationally through its international collaborations and its scientific publications in specialised journals.

> www.crp-sante.lu

Prof Rudi BALLING recruited as Director of new Centre for Systems Biology

Luxembourg, 17th July 2009 - The University of Luxembourg has appointed the new Director of the future Centre for Systems Biology. Prof Dr Rudi BALLING (55), currently Scientific Director of the Helmholtz Centre for Infection Research in Braunschweig, will join the multilingual research university in Luxembourg as of January 2010.

Born in the Eifel the renowned geneticist will pioneer biomedical research in the Grand Duchy of Luxembourg. «Putting Luxembourg on the international map of biology and genome research is an exciting challenge » says BALLING. The Centre for Systems Biology (Centre for Systems Biology – Luxembourg, CSBL) of the University is part of a major governmental initiative, with the strategic goal to develop Luxembourg into a competence centre of molecular medicine and research in the area of personalised medicine. The recently established « Integrated Biobank of Luxembourg » is also part of this important project.

The CSBL is the second « Interdisciplinary Centre » of the University. Already at the beginning of 2009 the « Interdisciplinary Centre of Security, Reliability and Trust » was founded. The CSBL will cooperate very closely with an elite american partner institute, the « Institute for Systems Biology » in Seattle.

The new centre will be located on the new university campus in Belval. Rudi BALLING has studied human and animal nutrition and received his Phd in Reproductive Biology from the University of Aachen. After his « Habilitation » in 1991 he carried out research in the Mount Sinai Research Hospital in Toronto, Canada and the Max Planck Institutes in Göttingen and Freiburg im Breisgau. In 1993, he became Director at the Helmholtz Center for Mammalian Genetics in Munich.

In 2001 he took over the position as Scientific Director of the Helmholtz Center in Braunschweig, a research center with close to 700 employees.

During the last 6 months, Rudi BALLING was a guest professor at the Broad Institute of MIT/Harvard University in Boston (USA).



> Prof Dr Rudi BALLING, Director of the Centre for Systems Biology

© Helmholtz-Zentrum für Infektionsforschung, Braunschweig



> The TherapyEdge Box (version 1.2)

TherapyEdge and RightToCare Successfully Launch the New TherapyEdge™ Down Referral Software Patient Management System

About TherapyEdge, Inc. and ABL, S.A.:

Advanced Biological Laboratories (ABL), S.A., is a biotech company co-founded in 2000 by Dr Chalom B SAYADA and Dr Jean-Claude SCHMIT as a spin-off from the European academic research center, CRP-Santé, Luxembourg and in 2004, acquired the control of TherapyEdge, Inc.

TherapyEdge is a biotech company founded in 2000 as a spin-off from Triangle Pharmaceuticals, Inc., which had been acquired by Gilead Sciences in December 2002.

TherapyEdge and ABL's expertise lies within infectious diseases, with particular focus on resistance patterns and clinical outcome predictors for HIV-1, tuberculosis, hepatitis, malaria and human papillomavirus (HPV) infections. ABL was selected to supply the technology platform to support the SPREAD HIV resistance study in 16 countries, the EuropeHIVResistance (European Union-sponsored program) in 32 countries, and is actively participating in both private- and public-sector research in the world.

The ViroScore Suite and TherapyEdge systems are used worldwide to support optimal clinical care for individuals with complex diseases. TherapyEdge and ABL have offices in the USA, Luxembourg, and South Africa, and partners in Asia.

For more information:

<http://www.therapyedge.com>

JOHANNESBURG (BUSINESS WIRE). TherapyEdge ABL and Right to Care are pleased to announce the first year experience of down referral (DR) using its proprietary

patient management electronic record system named TherapyEdge™ Down Referral Module, presented at the 4th Southern African AIDS conference (Durban, April 2009).

The poster # 269 is describing the successful implementation of a Decision Support and Management Electronic System (TherapyEdge™) for Down Referral of HIV Patients on HAART to a Primary Health Care (PHC) Centre in South Africa. Few patients were lost to follow up (<2%) and 70% of defaulters were traced and are back in care, maintaining the HIV patients' data simultaneously over the network of initiation (PHC and sister clinic sites). HIV treatment monitoring by PHC nurses shows that a task shifting model is possible when facilitated by an expert system under the supervision of the trained health workers. More details about the one-year experience available at http://www.ablsa.com/site/en/product_rc.html.

In response to the global HIV crisis, TherapyEdge and Right to Care have developed a model of care for antiretroviral therapy treated patients from treatment initiation sites to primary health care centres, an activity which is termed "Down Referral". Down Referral is a mechanism to increase access to care for large number of patients requiring Anti-RetroViral (ARV) therapy in resource poor countries with a high prevalence of HIV-1 infection, and a shortage of trained health workers.

The high demand for services coupled with limited human resources creates an incredible strain on health professionals and HIV clinics.

Down referral to primary health care sites often ensures that patients receive treatment within walking distance of their homes, reducing the financial burden associated with transport and loss of income for clinical visits. Access to treatment sites is essential to treatment continuity and adherence.

RightToCare and TherapyEdge actively cooperated to develop innovative solutions for efficiently scaling up the ARV programme using a decentralised ARV procurement network to existing primary health care clinics and at the same time maintain optimal control and traceability of the HIV patient, optimal disease management under the supervision of the medical doctors, and reduce the HIV patient's "lost-to-follow-up".

The TherapyEdge™ Down Referral Module uses data collections and decision support based innovations, coupled with simple real-time connectivity, which are at the level of every HIV clinic in emerging countries. It helps ensure close monitoring of the HIV patients at every step of the down referred procedure.

.../...

"This new patient management tool development is vital if we are going to reach the target set by President ZUMA of 80% ARV treatment for all those in need, or 3 million patients on treatment by 2011, yet maintain optimal disease management without loss-to-follow-up" says Professor Ian SANNE, Managing Director at Right to Care, and Associate Professor Infectious Disease University of the Witwatersrand. SANNE's reference is to the government's National Strategic Plan 2007-2011, announced in 2007, and supported by President ZUMA.

By efficiently decentralising treatment, the systemised down referral model of care, facilitated by the decision and management electronic system will enable the expansion of ARV provision through existing primary health care infrastructures and primary health care nurses. Improved service delivery and electronic information systems deployed at sites including shorter waiting times, planned pharmacy supply has led to larger quantities of patients seen by trained primary health nurses and counsellors. The extension of this model to other sites, including private practitioners, could be a major step forward in managing South Africa's ambitious ARV roll out program, and will provide ongoing provision of technical assistance to government policy makers in HIV care and treatment.

Relevant links:

http://www.usaid.gov/our_work/global_health/aids/TechAreas/caresupport/arvfactsheet.html

<http://www.righttocare.org/content/view/50/85/>

<http://www.righttocare.org>

<http://www.therapyedge.com>



For more information, please contact:

ABL S.A. TherapyEdge Luxembourg

Dr Chalom SAYADA (Managing Director)

Email: chalom@ablsa.com

Mr Ronan BOULME (Director of Research and Development)

Email: ronan@ablsa.com

Tel: (+352) 2638 8921 | Fax: (+352) 2638 8938

ABL TherapyEdge South Africa Pty

Ron SNAPPER

Email: ron@therapyedge.com

Right to Care

Bruce CONRADIE

Email: bruce.conradie@righttocare.org

New Research Laboratory at the Public Research Centre Gabriel Lippmann

The engineered fabrication of materials at the nanometer-scale allows the development of innovative materials with incredible optical, mechanical, physical, chemical and biological properties. The advanced nano-processes for biological purposes opens a wide scope of applications to create innovative products with, for example, self-cleaning, bacteria-free, nano-structured coatings.

To address these strong potentials, a Nanomaterials research unit has recently been launched at the Centre Gabriel Lippmann to enhance collaborative R&D with Luxembourgish industrials.



**Centre de Recherche Public
Gabriel Lippmann**

For more information, please contact:


Dr Damien LENOBLE

Email: lenoble@lippmann.lu

Chinese Medicinal Plant Research at the Plant Molecular Biology Laboratory - CRP-Santé

The Plant Molecular Biology Laboratory, part of the Department of Virology, Allergology and Immunity of the CRP-Santé, is coordinating a collaborative research project on identifying and characterising novel lead therapeutic compounds against cancer based on current knowledge from Traditional Chinese Medicine. Partners in the project are the Gade Institute - University of Bergen (Norway), the Modern Research Centre of Traditional Chinese Medicine (MRCTCM) Shanghai (P. R. China), and the Institute of Medicinal Plant Development (IMPLAD) Beijing (P. R. China).

The project is co-funded by the European Commission (Programme "PEOPLE" - Call FP7-PEOPLE-IRSES-2008) and involves a 132 person per month scientist exchange between the European and Chinese partner institutions over the next four years.
.../...



© CRP-SANTE

> Left to right:
Ms Sun LIHUA, Ms Wang QIONG - IMPLAD (Beijing)

.../... Sun LIHUA and Wang QIONG from IMPLAD (Beijing) are the first two exchange scientists to visit CRP-Santé for a period of 90 days. LIHUA and QIONG are second-year PhD students at the Research Centre for Pharmacology and Toxicology, Institute of Medicinal Plant Development (IMPLAD) Beijing, which is affiliated with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC).

Born in Jilin Province (P. R. China), Sun LIHUA studied Clinical Medicine at Beihua University of Jilin from 1996-1999.

From 1999-2003 she worked as a physician at a country hospital of Traditional Chinese Medicine in Fusong, Jilin Province. She subsequently studied Pathology and Pathophysiology at the Department of Basic Medicine, Zhengzhou University (Henan Province) where she received a Masters degree in Medicine in 2006. Sun LIHUA's thesis research is on anti-leukaemia components from Chinese traditional herbs.

Native from Sichuan Province, P. R. China, Wang QIONG received her Bachelors degree in Clinical Medicine at the Department of Clinical Science of Liuzhou Medical College, Liuzhou (Sichuan Province) in 2001.

From 2001-2005 her studies at the Department of Basic Medicine at Liuzhou Medical College focused on cell cultures (primary neuron cells and cancer cells).

Since 2005, Wang QIONG has been working at IMPLAD in Beijing, where she has been trained in neuro-pharmacology of Chinese medicinal herbs. In particular, she set up and improved methodologies for behavioural tests in rodents (computer-based imaging-processing for animal locomotor activity test, computer-aided automatic control system for measuring step-down performance in rodents).

She is very familiar with experimental research on nootropic drugs from Chinese herbs in vivo and in vitro. Wang QIONG's thesis work is on improving learning and memory with Chinese ginseng and on neuro-biological mechanisms of ginsenosides on Alzheimer's disease.

For more information, please contact:

Sun LIHUA

Email: sunlihuaster@gmail.com

Wang QIONG

Email: luyiwangqiong@163.com

A road map for the development of the European Agro-food industry

The European Union's food industry cannot escape the current economic slowdown. Before giving this important industrial sector some momentum, Günter VERHEUGEN, Vice-president of the European Commission and Commissioners Mariann FISCHER BOEL and Meglena KUNEVA examined, along with other interested parties, the progress of the high level group's recommendations created on 7th March 2009.

For more information:

http://ec.europa.eu/enterprise/sectors/food/competitiveness/high-level-group/documentation/index_en.htm

ZOOM ON

Simeda Medical S.A.

Created in 2007 as a spin-off company from the Gottschol Alcuilux Industrial Group, Simeda S.A. benefits from over 40 years of experience in machining techniques. Simeda S.A. as a specialist in dental computer-aided design (CAD) and computer-aided manufacturing (CAM), proposes and commercialises a complete and open solution, including a scanner to digitalise models, creation and modification software, as well as a milling centre equipped with the latest high performance machinery to produce zirconium, titanium and CoCr parts.

In the dental field, which is the core business, Simeda S.A. markets a totally digitised production system comprised of scanners that enable 3D mapping of the prostheses environment and design software for prosthetics modelling developed from specifications drawn up in response to the requirements of prosthodontists and dental surgeons worldwide. Both standard repair work and implant work are possible using this software.

Indeed, digitalisation of the dental value chain is one of the key drivers in dentistry. Tooth restoration is increasingly driven by CAD and CAM of the prosthetics. Modern dental prosthetic inlays, crowns, and bridges are designed by computer and then milled by computerised machines from metals and ceramics. This procedure is considerably more efficient and is increasingly replacing traditional labour-intensive processes such as casting, layering and firing. Simeda S.A. offers a completely open scanning and conception solution, in a neutral STL industrial format which totally guarantees flexibility, quality and reactivity.

The STL files are transmitted to Simeda for processing in its milling centre, equipped with the latest generation 5-axes machining centres, enabling the production of complex and precise prostheses and associated equipment in zirconium, titanium, CoCr and resin.

Simeda S.A. guarantees a flexible solution, compatible with the industrial norms which allow dental laboratories to avoid closed systems. The industrial processes of scanning, conception and production allow Simeda S.A. to take on board the most complex applications.

The Simeda team brings together multilingual mechanical engineers and dental technicians (English, French and German) specialised in CAD/CAM and reverse engineering. An established partnership with European research centres enables them to be efficient and responsive.

Simeda S.A. sees itself as entering into a partnership with its customers, taking into consideration specific needs and requirements, so as to participate in their development and technical evolution. It makes the effort to fulfil all of its customers needs.

Simeda's know-how makes it an expert in the development and manufacturing of complex dental and medical prostheses in zirconium oxide (technical ceramic), titanium and Chrome-Cobalt.

Moreover, Simeda S.A. has recently received the quality management certifications ISO 9001:2008 / ISO 13485:2003 and the CE Marking regarding the Council Directive 93/42/EEC concerning medical devices.

> www.simeda-medical.com



© SIMEDA

CALL FOR PROPOSALS

> **National Research Fund (FNR)**

Fonds National de la
Recherche Luxembourg

CORE PROGRAMME

December 2009: Publication of a new call which will also cover the domain Biomedical Sciences / Regulation of Chronic, Degenerative and Infectious Diseases (BM) with its sub-domains:

- Regenerative Medicine in Age-related Diseases,
- Translational Biomedical Research, and
- Public Health.

> For more information on the CORE Programme:

<http://www.fnr.lu/en/Grants-Activities/Research-Programmes/CORE-Programme>

ATTRACT PROGRAMME - Opportunities for Outstanding Young Researchers in Luxembourg

November 2009: Publication of a new call. No thematic limitations; however, projects must be submitted jointly with a public-sector research institution in Luxembourg.

> For more information on the ATTRACT Programme:

<http://www.fnr.lu/en/Grants-Activities/Research-Programmes/ATTRACT-Programme>

In the framework of its **INTER PROGRAMME - Promotion of International Collaboration**, the FNR is participating in the ERA-Net SysBio (Systems Biology).

First calls in the framework of ERA SysBio are foreseen in 2010.

> For more information on the ERA-Net:

<http://www.erasysbio.net/>

In the framework of its **BIOSAN-PROVIE PROGRAMME**, The FNR has already financed several projects in the domain of Biotechnology and Health & Medical Aspects of Ageing.

> For more information on the BIOSAN-PROVIE Programme and projects:

<http://www.fnr.lu/en/Grants-Activities/Research-Programmes/BIOSAN-PROVIE-Programme>

AGENDA

LUXEMBOURG

> **SEPTEMBER 2009**

29th International Day of Clinical Biology

18th - 19th September 2009

Centre Culturel Prince Henri - Walferdange

<http://www.slbc.lu/index.php?id=13>

1st Cytometry Summer Course

22nd September 2009

2.00pm - 6.00pm

Amphitheatre - Centre Hospitalier du Luxembourg

<http://www.innovation.public.lu/html/agenda/event.jsp?idUrl=7998>

CIEC Clinical Research Day

25th September 2009

8.30am - 5.30pm

Hôtel-Park Bellevue - Luxembourg

<http://www.crp-sante.lu/en/blog/1201?year=>

> **OCTOBER 2009**

2nd Bioinformatics Meeting in Luxembourg - LuciLinX 2009

9th October 2009

University of Luxembourg

<http://www.lucilinx.lu/>

> **NOVEMBER 2009**

Sciences Festival 2009

12th to 15th November 2009

<http://www.science-festival.lu/fr/programme.aspx>

Workshops:

Virtual reality

The mind makes it real

Institution: CRP-Santé - Laboratory for Emotional Troubles

The virus: the perfect strategist!

Institution: CRP-Santé

Man, plants and cancer

Institution: Laboratory for Molecular and Cellular Biology

In vitro culture

Institution: CRP-Gabriel Lippmann

4th Luxembourg Cytometry Meeting

25th November 2009

1.30pm - 6.00pm

Amphitheatre - Centre

Hospitalier du Luxembourg

<http://www.innovation.public.lu/html/agenda/event.jsp?idUrl=7997>

> The 7th Framework Programme (FP7)



HEALTH THEME

The objective of health research under FP7 is to improve the health of European citizens and boost the competitiveness of health-related industries and businesses, as well as address global health issues.

> For more information: http://cordis.europa.eu/fp7/health/home_en.html

Several Calls for proposal will be published on the **30th July 2009** with an estimated budget of 638 240 000 Euros. The main focus will be on the following three key challenges:

- Providing tools for translational research;
- Structuring translational research in the field of cancer;
- Structuring translational research in the field of neurodegenerative diseases.

> The Call will be made available for download after publication at the following link:

<http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.FP7CallsPage>

FOOD, AGRICULTURE AND FISHERIES AND BIOTECHNOLOGY THEME

The primary aim for the funding of the 'Food, Agriculture and Fisheries, and Biotechnology' research theme under the Seventh Framework Programme (FP7) is to build a European Knowledge Based Bio-Economy (KBBE).

The 'Food, Agriculture and Fisheries, and Biotechnology' theme is built around three major activities:

- sustainable production and management of biological resources from land, forest and aquatic environments;
- fork to farm: Food (including seafood), health and well-being;
- life sciences, biotechnology and biochemistry for sustainable non-food products and processes.

Several Calls for proposal will be published on the **30th July 2009** with an estimated budget of 220 690 000 Euros.

> The Call will be made available for download after publication at the following link:

<http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.FP7CallsPage>

AGENDA

> JANUARY 2010

Inflammation 2010: Inflammatory cell signalling mechanisms as therapeutic targets

27th to 30th January 2010

Hôpital de Kirchberg

<http://www.lbmcc.lu>

> APRIL 2010

Med-e-Tel

14th to 16th April 2010

Luxexpo

<http://www.medetel.lu/index.php>

INTERNATIONAL

> SEPTEMBER 2009

The EMBO Meeting 2009

29th August to 1st September 2009

Amsterdam (The Netherlands)

Prof. Jules HOFFMANN (EMBO member and researcher from Luxembourg) will chair a workshop on 30th August 2009.

<http://www.the-embo-meeting.org/>

22nd European Conference on Biomaterials

7th to 11th September 2009

Lausanne (Switzerland)

<http://www.esb2009.org/welcome/index.php>

Biomarkers in Clinical Trials

23rd to 24th September 2009

Crowne Plaza, St. James

London (United Kingdom)

<http://www.innovation.public.lu/html/agenda/event.jsp?idUrl=7939>

EUROBIO

23rd to 25th September 2009

Lille, Grand Palais (France)

<http://www.eurobio-event.com/editorial.php>

Trends in Translational Cancer Research

28th to 29th September 2009

Bergen (Norway)

<http://www.uib.no/med/moleculartargets/>

INNOVATIVE MEDICINE INITIATIVE (IMI)

The Innovative Medicines Initiative is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Communities represented by the European Commission.

> For more information: http://imi.europa.eu/index_en.html

Professor Michel GOLDMAN appointed as Executive Director

At the meeting held on the 10th June 2009 the Innovative Medicines Initiative Joint Undertaking's Governing Board took the decision to appoint Professor Michel GOLDMAN as Executive Director of the IMI JU.

> For more information:

http://imi.europa.eu/executive-director_en.html

The 2nd Call will be published in September 2009 with a budget of 150 million Euros.

The scientific priorities are already available on:

http://imi.europa.eu/docs/draft-imi-ju-scientific-priorities-2009_en.pdf

EDITORIAL BOARD

Aurélia DERISCHEBOURG, CRP - Santé

Monia DI PILLO, CRP - Henri Tudor

Xavier FELLER, Luxinnovation

Oliver MARQUIS, CRP - Gabriel Lippmann

Britta SCHLÜTER, University of Luxembourg

Anne SCHROEDER, National Research Fund

Céline TARRAUBE, Luxinnovation

CONTACTS & SUBSCRIPTION

Ms Céline TARRAUBE - BioHealth Cluster Manager

> If you would like to have an article published in our newsletter or wish to be included in the mailing list, please contact us at:

celine.tarraube@luxinnovation.lu

Luxinnovation GIE

7, rue Alcide de Gasperi

L-1615 Luxembourg

Phone: +352 43 62 63 1

Fax: +352 43 81 20

www.biohealth.lu - www.luxinnovation.lu

Register now, become a member of the Luxembourg Portal for Innovation and Research! www.innovation.public.lu

The BioHealth newsletter is edited by Luxinnovation GIE.
This newsletter is published twice per year.



© LUXINNOVATION GIE 2009

AGENDA

> OCTOBER 2009

Conducting Clinical Trials in Europe
12th to 13th October 2009 Crowne
Plaza Hotel - St James, London
(United Kingdom)

<http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3154>

Nutraceuticals and Functional Foods
21st to 22nd October 2009 Crowne
Plaza Hotel - St James, London
(United Kingdom)

<http://www.smi-online.co.uk/events/overview.asp?ref=3158>

Food Industry Congress
Innover à coûts maîtrisés en
agroalimentaire
22nd October 2009
Paris (France)

<http://www.usinenouvelle.com/article/congres-industrie-agroalimentaire.N70147>

> NOVEMBER 2009

Bio-Europe 2009
2nd to 4th November 2009
Vienna (Austria)

<http://www.ebdgroup.com/bioeurope/>

International Days of Biology
3rd to 6th November 2009
Paris (France)

<http://www.jib-sdbio.fr>

4th International Symposium on
Recent advances in food analysis
4th to 6th November 2009 Prague
(Czech Republic)

<http://www.rafa2009.eu/Default.aspx>

eHealth 2009
18th to 20th November 2009 Prague
(Czech Republic)

http://ec.europa.eu/information_society/newsroom/cf/itemdetail.cfm?item_id=4507

MEDICA
18th to 21st November 2009 Messe
Düsseldorf
Düsseldorf (Germany)

http://www.medica.de/cipp/md_medica/custom/pub/content,lang,1/oid,155/ticket,g_u_e_s_t/~ /MEDICA_Home.html